Biostage (NSDQ:BSTG) this week announced that its Cellspan Esophageal Implant investigational new drug application won FDA approval. The Cellspan Esophageal Implant is designed to treat patients with end-stage esophageal disease that require segmental surgical resection to repair diseased tissue. Biostage announced the first patient was treated with the esophageal implant in August 2017. The device was […]
Biostage
First patient treated with Biostage’s esophageal implant
Biostage (NSDQ:BSTG) touted today the first patient use of its Cellspan esophageal implant. The Holliston, Mass.-based company said that the regenerative implant was used in a 75-year old male patient, who has a life-threatening cancerous mass in his chest. Surgeons removed the portion of his esophagus affected by the cancer and Biostage’s implant was used […]
Biostage prices $8m offering for bioengineered organ implant
Biostage (NSDQ:BSTG), a 27-person biotech based in Holliston, Mass., is developing technology to regrow esophageal tissue in patients that have esophageal cancer or atresia. Last week, the company priced a public offering at ¢40 per share of common stock, expecting to bring in $8 million from the round. The current standard of care for resectable […]